Research Highlights/News

2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012

»  Look for consumer stories click here

2024:

Press Releases:

• Defense Health Program Department of Defense Duchenne Muscular Dystrophy Research Program Anticipated Funding Opportunities for Fiscal Year 2024 (FY24)
  April 5, 2024

2023:

Press Releases:

• CDMRP-Funded Research Contributed to a Recently FDA-Approved Drug for Duchenne Muscular Dystrophy
  November 3, 2023

• Defense Health Program Department of Defense Duchenne Muscular Dystrophy Research Program Anticipated Funding Opportunities for Fiscal Year 2023 (FY23)
  May 5, 2023

Research Highlights:

• Toward a Safer and Better Gene Therapy for Duchenne Muscular Dystrophy

2022:

Press Releases:

• Defense Health Program Department of Defense Duchenne Muscular Dystrophy Research Program Anticipated Funding Opportunities for Fiscal Year 2022 (FY22)
  May 5, 2022

2021:

Press Releases:

• Defense Health Program Department of Defense Duchenne Muscular Dystrophy Research Program Anticipated Funding Opportunities for Fiscal Year 2021 (FY21)
  April 28, 2021

Research Highlights

• New Potential Antibody Treatment for Duchenne Muscular Dystrophy

News:

• Santhera and ReveraGen Announce Positive and Statistically Highly Significant Topline Results with Vamorolone in Pivotal VISION-DMD Study (external link)
  Santhera, June 7, 2021

2020:

Press Releases:

• Defense Health Program Department of Defense Duchenne Muscular Dystrophy Research Program Anticipated Funding Opportunities for Fiscal Year 2020 (FY20)
  May 13, 2020

Research Highlights

• Steps Forward in Treating Duchenne Muscular Dystrophy with Gene Repair Therapy

News:

• Completion of Long-Term Extension Study with Vamorolone in Duchenne Muscular Dystrophy (external link)
  Santhera, June 3, 2020
• JAMA Neurology Publication of Clinical Trial Data for Viltolarsen in DMD Patients (external link)
  CISION PR Newswire, May 29, 2020

2019:

Press Releases:

• Department of Defense Duchenne Muscular Dystrophy Research Program Anticipated Funding Opportunities for Fiscal Year 2019 (FY19)
  May 1, 2019

News:

• CRISPR Fix in Mice May Lead to Muscular Dystrophy Therapy (external link)
  Futurity, October 8, 2019
• Vamorolone Treatment of Duchenne Muscular Dystrophy Patients Leads to Improvements in Motor Function (external link)
  ReveraGen, September 6, 2019
• Single CRISPR Treatment Provides Long-Term Benefits in Mouse Models of Duchenne (external link)
  Duke University - Pratt School of Engineering, February 22, 2019
• Researchers Overcome Hurdle in CRISPR Gene Editing for Muscular Dystrophy (external link)
  University of Missouri Health, January 15, 2019

2018:

Press Releases:

• Department of Defense Duchenne Muscular Dystrophy Research Program Anticipated Funding Opportunities for Fiscal Year 2018 (FY18)
  May 15, 2018

Research Highlights

• AAV Vectors, A Step Toward Duchenne Muscular Dystrophy Clinical Trials

News:

• Investigational steroid mirrors prednisone's benefits while taming its side effects (external link)
  EurekAlert!, September 25, 2018

2017:

Press Releases:

• Department of Defense Duchenne Muscular Dystrophy Research Program Anticipated Funding Opportunities for Fiscal Year 2017 (FY17)
  March 31, 2017

Research Highlights

• Preclinical Testing of a Novel Method to Block TGFbeta Family Proteins in DMD

News:

• FDA Grants RASRx1902 Orphan Drug Status as Potential Therapy for Duchenne Muscular Dystrophy (external link)
  Muscular Dystrophy News Today, June 23, 2017

2016:

Press Releases:

• Department of Defense Duchenne Muscular Dystrophy Research Program Funding Opportunities for Fiscal Year 2016
May 2, 2016

News:

• Actelion obtains an option to in-license vamorolone, a novel treatment for Duchenne, from ReveraGen (external link)
  ReveraGen, November 14, 2016
• Gene editing offers hope for treating Duchenne Muscular Dystrophy (external link)
  The New York Times, January 11, 2016

2015:

Press Releases:

• Department of Defense Duchenne Muscular Dystrophy Research Program Funding Opportunities for Fiscal Year 2015
May 4, 2015

2014:

Press Releases:

• Department of Defense Duchenne Muscular Dystrophy Research Program Funding Opportunities for Fiscal Year 2014
May 1, 2014

2013:

Press Releases:

• Department of Defense Duchenne Muscular Dystrophy Research Program Funding Opportunities for Fiscal Year 2013
April 19, 2013

Research Highlights:

• A Potential New DMD Therapeutic
• DMD Diagnostic Optical Imaging
• New Clinical Outcome Measurements
• GALGT2 Gene Therapy

News:

• New Muscular Dystrophy Treatment Shows Promise in Early Study Led by Children's National (external link)
  Children's National Health System, October 2, 2013

2012:

Press Releases:

• Department of Defense Duchenne Muscular Dystrophy Research Program Funding Opportunities for Fiscal Year 2011
August 23, 2011

News:

• Sarepta Therapeutics Announces Significant Clinical Benefit With Eteplirsen (external link)
  Sarepta Therapeutics, August 17, 2012

Top of Page